

Geoffrey Joyce
USC Schaeffer Center, Verna & Peter Dauterive Hall (VPD)
635 Downey Way, Los Angeles, CA 90089-3333
Phone: (213) 821-7958, Fax : (213) 740-3460, E-mail: gjoyce@usc.edu

PROFESSIONAL EXPERIENCE:

Director of Health Policy, Leonard D. Schaeffer Center for Health Policy & Economics, 2009-
Research Associate, National Bureau of Economic Research, 2011-
Senior Economist, RAND Corporation, 2005-2009
Economist, RAND Corporation, 2002-2005
Associate Economist, RAND Corporation, 2000-2002

ACADEMIC EXPERIENCE:

Associate Professor and Chair (2015), Department of Pharmaceutical & Health Economics,
University of Southern California, 2009-
Professor, Pardee RAND Graduate School, 2006-2009
Adjunct Associate Professor, UCLA School of Public Health, 2005-2019
Co-Director, UCLA/RAND Health Services Research Training Program, 2004-

EDUCATION:

Ph.D. in Economics, City University of New York
MPP, Ford School of Public Policy, University of Michigan
B.A. in Economics and Political Science, Connecticut College

FUNDED RESEARCH:

Co-Investigator (Zhou, PI). "Low-Value Services Use Among Older Adults with Cardiometabolic Conditions". AIM-AHEAD Consortium Development Program, National Institutes of Health. Grant Number 1OT2OD032581-02-338. October 2023-September 2024 (\$478,000).

Co-Investigator (Qato, PI). "Structural Racism in Medicare Part D, Pharmacy Closures and Disparities in Medication Adherence in Older Adults". National Institute on Aging, Grant Number 1R01AG080090-01. July 2023-June 2026 (\$1,650,000).

Co-Investigator (Zissimopoulos, Bennett, PIs). "Use and Impact of Novel and Repurposed Therapeutics for Alzheimer's Disease and Related Dementia in Diverse Populations". National Institute on Aging, Grant Number R61 AG081811. July 2023-June 2028 (\$2,602,384).

Principal Investigator. "Evidence for Value-based Prescription Drug Plan for Diabetes, CVD and Chronic Illness". National Institute on Aging, Grant Number: R01AG059234. September 2019 – April 2024 (\$1,347,497).

Co-Investigator (Trish, PI). Evaluating Policy-Relevant Trends in the Medicare Part D Market Commonwealth Fund and Laura and John Arnold Foundation 7/2020-12/2021 (\$252,577).

Co-Investigator (Zissimopoulos, PI) “Effectiveness of Therapeutics and Health Care Services in Reducing Racial Disparities in Alzheimer's Disease”. National Institute on Aging, R01AG055401-01A1, Oct 2017-May 2020 (\$2,497,938).

Principal Investigator “The Impact of Prior Authorization”. American Medical Association, June 2016- June 2017 (\$349,049).

Co-Investigator (Trish, PI). Exploring the Relationship between Provider Prices for Commercial and Medicare Advantage Enrollees. RWJF Changes in Healthcare Financing and Organization Initiative 5/2015-11/2016 (\$170,406).

Principal Investigator “Integrating Clinical Pharmacy Services in Safety-Net Clinics”. Centers for Medicare and Medicaid Services, 1C1CMS331040-01-00, July 2012- June 2016 (\$12,007,677).

Co-Investigator (Goldman, PI) “An Economic and Behavioral Evaluation of Medicare Part D”. National Institute on Aging (P01AG033559), 2011-2016 (\$3,170,745).

Principal Investigator. Medco/RAND Center for Healthy Action. Medco Health Solutions. May 2009-April 2011 (\$750,000).

Principal Investigator. “Extreme Cost-Sharing for Specialty Drugs and Their Association with Medical Service Use.” Amgen, Inc., November 2008 – October 2009 (\$350,000).

Principal Investigator. “The Value of Broad Pharmaceutical Formularies: A Replication-of-Failure Analysis.” Janssen Pharmaceuticals, November 2008 – October 2009 (\$350,000).

Co-Principal Investigator (with D. Goldman). "Improving Pharmacy Benefit Design". National Institute on Aging, Grant Number: 1R01AG029514 - 01A2. August 2008 – July 2012 (\$1,200,000).

Principal Investigator. “The Social Benefits of More Generous Medicaid Formulary Policies for Antipsychotics.” Janssen Pharmaceuticals, December 2007 – December 2009 (\$998,000).

Co-Principal Investigator (with D. Goldman). “High Deductible Plans and Use of Preventive Services.” Centers for Disease Control, July 2007 – June 2009 (\$150,000).

Co-Principal Investigator (with D. Goldman). “High Deductible Plans and Prescription Drug Utilization.” Merck & Company, July 2007 – June 2009 (\$200,000).

Principal Investigator. “Medicare Part D: Framework for Understanding Potential Structural Changes & Comparing Pharmacy Benefit Programs”. UnitedHealthGroup, June 2007 – December 2007 (\$450,000).

Principal Investigator. “Examining the Impact of the New Medicare Drug Benefit in California.” California HealthCare Foundation, January 2007 – January 2008 (\$324,771).

Principal Investigator. Follow-up funding for “Understanding How Cost-Sharing Affects Use of Drugs for Treating Rheumatoid Arthritis.” Genentech, Inc., January 2007-July 2007 (\$125,000).

Principal Investigator. “Cost-Sharing Trends for Specialty Drugs and Their Association with Medical Service Use.” Amgen, Inc., July 2006 – June 2007 (\$375,000).

Co-Principal Investigator (with D. Goldman). “Understanding How Cost-Sharing Affects Use of Drugs for Treating Rheumatoid Arthritis.” Genentech, Inc., Dec. 2005-June 2006 (\$300,000).

Principal Investigator. “Analysis of Pharmaceutical Assistance Initiatives on the 2005 Special Election Ballot.” California HealthCare Foundation (\$125,000).

Co-Principal Investigator (with D. Goldman). “Benefit Gaps and Their Impact on Pharmaceutical and Medical Use of the Elderly.” National Institute of Aging, Administrative Supplement (\$169,323).

Principal Investigator. “The Costs of Chronic Illness among the Elderly”. National Institute of Aging / RAND Roybal Center (\$60,000).

Principal Investigator. “Understanding How High-Cost Patients Respond to Pharmacy Benefit Changes.” Amgen, Inc., Nov. 2004-Dec. 2005 (\$325,000).

Co-Principal Investigator (with D. Goldman). “The Costs of Treating Chronic Disease in the United States and Germany.” Techniker Krankenkasse, Nov. 2004-Dec. 2005 (\$250,000).

Principal Investigator. “Costs of Severe Chronic Illness among the Elderly.” UCLA Claude D. Pepper Center (OAIC), Career Development Award, 2003-2006 (\$120,000).

Principal Investigator. “The Impact of Drug Benefits on Pharmaceutical Use, Medication Compliance and Medical Care Utilization.” Agency for Healthcare Research and Quality, October 2002-September 2004, R03HS13447-01 (\$99,993).

Principal Investigator. “A Simulation Model of Pharmaceutical Use by Medicare-Eligible Tricare Beneficiaries.” Department of Defense, March 2003-June 2004 (\$250,000).

Principal Investigator. “Use of Pharmaceuticals by Medicare-Eligible Tricare Beneficiaries.” Department of Defense, June 2002-June 2004 (\$325,000).

Co-Principal Investigator (with D. Goldman). “The Impact of Prescription Drug Benefit and Formulary Designs on Pharmaceutical Use and Costs.” California HealthCare Foundation, March 2003-December 2003 (\$92,000).

Co-Principal Investigator (with D. Goldman). “The Impact of Prescription Drug Benefits on Utilization and Costs.” Merck, July 2002-December 2003 (\$135,000).

Co-Principal Investigator (with D. Goldman). “The Impact of Prescription Drug Benefit and Formulary Designs on Pharmaceutical Use and Costs.” California HealthCare Foundation, August 2000-June 2002 (\$700,000).

PUBLICATIONS:

A. Journal Articles

Joyce G, Blaylock B, Chen J, Van Nuys, K. The Use of Utilization Restrictions in Medicare Part D Plans. *Health Affairs* (Forthcoming)

Zissimopoulos J, **Joyce G**, Jacobson M. Trends in Incident Dementia Diagnosis Before and After Medicare Risk Adjustment. *JAMA Network Open*. 2023;6(12):e2347708. doi:10.1001/jamanetworkopen.2023.47708.

Joyce G, Zhou B, Kaestner R. Why Higher Copayments for Opioids Did Not Reduce Use Among Medicare Beneficiaries. *Health Economics*. 2023; 1-16. doi: 10.1002/hec.4779.

Haye, S., Thunell, J., **Joyce, G.**, Ferido, P., Tysinger, B., Jacobson, M., & Zissimopoulos, J. (2023). Estimates of diagnosed dementia prevalence and incidence among diverse beneficiaries in traditional Medicare and Medicare Advantage. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring*, 15(3), e12472.

Xu J, Trish E, **Joyce G**. Part D Beneficiaries' Incentives and Responses under Preferred Pharmacy Networks. *The American Journal of Managed Care*. 2023;29(4).

Trish E, Kaiser KM, Celestin J, **Joyce G**. Reforming Medicare Part D Benefit Design: Financial Implications for Beneficiaries, Private Plans, Drug Manufacturers, and the Federal Government. *Journal of Health Politics, Policy and Law*. 2022; 10041233. <https://doi.org/10.1215/03616878-10041233>.

Zhou B, Goldman D, Seabury S. **Joyce G**. The Clinical Consequences of Prior Authorization – The Case of Novel Anticoagulants. *American Journal of Managed Care*. 2022;28(10):521-528. <https://doi.org/10.37765/ajmc.2022.89195>.

Ng Th, Oh EE, Bae-Chaw Y, Minejima E, **Joyce G**. Acute Bacterial Infections and Longitudinal Risk of Readmissions and Mortality in Patients Hospitalized with Heart Failure. *J. Clin. Med*. 2022 Jan 29;11(3):740. doi: 10.3390/jcm11030740.

Joyce G, Thunell J, Ferido P, Tysinger B, Zissimopoulos J. Benzodiazepine Use and the Risk of Dementia. *Alzheimer's & Dementia: Translational Research & Clinical Interventions* 2022;8:e12309. <https://doi.org/10.1002/trc2.12309>.

Xu J, Trish E, **Joyce G**. Medicare Part D Beneficiaries' Pharmacy Switching in Response to Preferred Pharmacy Networks. *Health Services Research*, March 17, 2022. <https://doi.org/10.1111/1475-6773.13973>.

Thunell J, **Joyce G**, Qato D, Guadamuz J, Zissimopoulos J. Diagnosis of Behavioral Symptoms of Dementia and CNS-Active Drug Use Among Diverse Persons Living With Dementia. *Innov Aging*. 2021 Dec 17;5(Suppl 1):271. doi: 10.1093/geroni/igab046.1055. PMID: PMC8679419.

Trish E, Van Nuys K, Ribero R, Gascue L, **Joyce G**. Medicare Overspending on Common Generic Drugs. *JAMA Internal Medicine*, October 2021, Volume 181, No. 10.

Thunell J, Chen Y, **Joyce G**, Barthold D, Shekelle P, Brinton RD, Zissimopoulos J. Drug Therapies for Chronic Conditions and Risk of Alzheimer's Disease and Related Dementias: A Scoping Review. *Alzheimers and Dementia*. January 2021, Volume 17, Issue 1, 41-48. doi.org/10.1002/alz.12175

Trish E, Kaiser K, **Joyce G**. Association of Out-of-Pocket Spending with Insulin Adherence in Medicare Part D. *JAMA Netw Open*. 2021;4(1): e2033988. [doi:10.1001/jamanetworkopen.2020.33988](https://doi.org/10.1001/jamanetworkopen.2020.33988).

Barthold D, **Joyce G**, Ferido P, Drabo EF, Marcum ZA, Gray S, Zissimopoulos J. Pharmaceutical treatment for Alzheimer's disease and related dementias: utilization and disparities. *Journal of Alzheimer's Disease*. 2020;76(2):579-589. doi: 10.3233/JAD-200133.

Buttorf C, Xu Y, **Joyce G**. Variation in Generic Drug Use in Medicare Part D. *American Journal of Managed Care*, November 2020, Volume 26, Issue 11.

Barthold D, **Joyce G**, Brinton RD, Wharton W, Kehoe PG, Zissimopoulos J. Association of Combination Statin and Antihypertensive Therapy with Reduced Alzheimer's Disease and Related Dementia Risk. *PLoS One*, Mar 4, 2020;15(3):e0229541.
doi: 10.1371/journal.pone.0229541. eCollection 2020.

Trish E, Ginsburg P, **Joyce G**, Goldman D. Who Pays in Medicare Part D? - It's Time to Give Plans More Skin in the Game. *New England Journal of Medicine*, November 20, 2019. DOI: 10.1056/NEJMp1912357

Drabo E, Barthold D, **Joyce G**, Ferido P, Zissimopoulos J. Longitudinal Analysis of Dementia Diagnosis and Specialty Care Among Racially Diverse Medicare Beneficiaries. *Alzheimer's & Dementia*, 2019; 1-10. <https://doi.org/10.1016/j.jalz.2019.07.005>

Xu J, Trish E, **Joyce G**. Incorporating Prescription Drug Utilization Information into the Marketplace Risk Adjustment Model Improves Payment Accuracy and Reduces Adverse Selection Incentives. *Medical Care Research and Review*, August 2019. <https://doi.org/10.1177/1077558719870060>.

Xie R, St. Clair P, Goldman D, **Joyce G**. Differences in Medication Adherence by Race, Ethnicity and Socioeconomic Status. *PLOS ONE*, February 14, 2019.
<https://doi.org/10.1371/journal.pone.0212117>.

Joyce G, Henkhaus L, Gascue L, Zissimopoulos J. Generic Drug Price Hikes and Patient Out-of-Pocket Costs for Medicare Beneficiaries. *Health Affairs*, 2018;37(10). doi/10.1377/hlthaff.2018.0628.

Van Nuys K, **Joyce G**, Ribero R and Goldman D. Frequency and Magnitude of Copayments Exceeding Prescription Drug Costs. *Journal of the American Medical Association (JAMA)*, 2018;319(10):1045-1047. doi:10.1001/jama.2018.0102.

Barthold D, **Joyce G**. Wharton W, Kehoe P, Zissimopoulos J. The Association of Multiple Anti-hypertensive Medication Classes with Alzheimer's disease Incidence Across Sex, Race and Ethnicity. *PLOS ONE*, November 1, 2018. <https://doi.org/10.1371/journal.pone.0206705>.

Trish E, Xu J, **Joyce G**. Growing Number of Unsubsidized Part D Beneficiaries with Catastrophic Spending Suggests Need for an Out-Of-Pocket Cap. *Health Affairs*. 37(7), 2018.

Carrera M, Goldman D, **Joyce G**, Sood N. Do Physicians Respond to the Costs and Cost-sensitivity of Their Patients? *American Economic Journal: Economic Policy*. 10(1), 2018.

Arora S, Sood N, Terp S, **Joyce G**. The Price May Not Be Right. The Value of Comparison Shopping for Prescription Drugs. *American Journal of Managed Care*. 2017.

Trish E, Ginsberg P, Gascue L and **Joyce G**. Physician Reimbursement in Medicare Advantage. *JAMA Internal Medicine*, doi:10.1001/jamainternmed.2017.2679. 2017.

Joyce G, Sood N. Why Medicare Price Negotiation is the Wrong Prescription for Rising Drug Spending: Response to Rena Conti. *Journal of Policy Analysis and Management*. 2016, DOI:10.1002/pam.21937.

Zissimopoulos J, Barthold D, Brinton R, **Joyce G**. Sex and Race Differences in the Association of Statin Use and Incidence of Alzheimer's Disease. *JAMA Neurology*, 2016. doi:10.1001/jamaneurol.2016.3783.

Trish E, Xu J, **Joyce G**. Medicare Beneficiaries Face Growing Out-of-Pocket Burden for Specialty Drugs While in the Catastrophic Coverage Phase. *Health Affairs*. 2016; 35(9): 1564-1571.

Joyce G, Sood N. Why Medicare Price Negotiation is the Wrong Prescription for Rising Drug Spending. *Journal of Policy Analysis and Management*. 2016, DOI: 10.1002/pam.21935.

Shin J, **Joyce G**, McCombs J. Outcomes Associated with Primary and Secondary Non-adherence to Cholesterol Medications. *Am J Pharm Benefits*, 2016; 8(2): 54-60.

Zissimopoulos J, **Joyce G**, Scarpati L, Goldman D. Did Medicare Part D Reduce Disparities? *American Journal of Managed Care*, 2015; 21(2): 119-128.

Trish E, **Joyce G**, Goldman D. Specialty Drug Spending Trends Among Medicare and Medicare Advantage Enrollees, 2007-11. *Health Affairs*, 2014; 33(11); 2018-24.

Stain SC, Hoyt DB, Hunter JG, **Joyce G**, Hiatt JR. American Surgery and the Affordable Care Act. *JAMA Surgery*, 2014; 149(9); 984-5.

Goldman, D, Fastenau J, Dirani R, Helland E, **Joyce G**, Conrad R, and Lakdawalla D. "Medicaid Prior Authorization Policies and Imprisonment Among Patients with Schizophrenia" *American Journal of Managed Care*, 2014;20(7); 577-86.

Joyce G, Zissimopoulos J, Goldman D. Digesting the Doughnut Hole. *Journal of Health Economics*, 2013; 32: 1345-55.

Darkow T, Maclean R, **Joyce G**, Goldman D, Lakdawalla D. Coverage and Use of Cancer Therapies in the Treatment of Chronic Myeloid Leukemia. *American Journal of Managed Care*. 2012; 18(11): S272-8.

Karaca-Mandic P, Jena AB, **Joyce GF**, and Goldman DP. "Out-of-Pocket Medication Costs, Medication Utilization, and Use of Health Care Services Among Children with Asthma. *Journal of the American Medical Association (JAMA)*. 2012; 307(12): 1284-1291.

Vogt W, **Joyce GF**, Xia J, Dirani R, Wan G, Goldman DP. Medicaid Cost Control Measures and Use of Psychiatric Drugs. *Health Affairs*. 2011, 30(12): 2346-2354.

Joyce GF, Carrera M, Goldman DP, Sood N. Physician Prescribing Behavior and Its Impact on Patient-Level Outcomes. *American Journal of Managed Care*. 2011, 17(12): e462-471.

Goldman DP, **Joyce GF**, and Vogt WB. Part D Formulary and Benefit Design as a Risk-Steering Mechanism. *American Economic Review*. 2011; 101 (May): 382-86.

Jena AB, Goldman DP, **Joyce GF**. The Association between the Birth of Twins and Parental Divorce. *Obstetrics & Gynecology*. 2011; 117(4); 892-897.

Meeker D, **Joyce GF**, Malkin J, Teutsch S, Haddiz A, Goldman DP. Does First-Dollar Coverage of Preventive Services Mitigate the Effects of High Deductibles? *Health Services Research*. 2011; 46(1): 173-184.

Joyce, GF. Understanding Primary Nonadherence. *American Journal of Pharmacy Benefits.* 2010; 2(2): 1-2.

Karaca-Mandic P, **Joyce GF**, Goldman DP, Laouri M. Price Sensitivity and the Use of Specialty Drugs for Rheumatoid Arthritis. *Health Services Research.* 2010; 45(5).

Joyce GF, Goldman DP, Vogt WB, Sun E, Jena AB. "Medicare Part D After Two Years". *American Journal of Managed Care.* 2009; 15(8): 536-544.

Solomon M, Goldman DP, **Joyce GF**, Escarce JJ. "Cost-Sharing and the Initiation of Drug Therapy for the Chronically Ill". *Archives of Internal Medicine.* 2009; 169(8): 740-48.

Joyce GF, Niaura R, Maglione M, Mongoven J, Larson C, Coan J, Lapin P, Morton SC. "The Effectiveness of Covering Smoking Cessation Services for Medicare Beneficiaries". *Health Services Research.* 2008; 6: 2106-2123.

Goldman DP, **Joyce GF.** "Medicare Part D: A Successful Start with Room for Improvement". *Journal of the American Medical Association (JAMA).* 2008; 299(16): 1954-1955.

Joyce, GF, Goldman DP, Karaca-Mandic P, Lawless G. "Impact of Specialty Drugs on the Use of Other Medical Services for Rheumatoid Arthritis and Multiple Sclerosis". *American Journal of Managed Care.* 2008; 14(12): 821-828.

Goldman DP, **Joyce GF**, Zheng Y. "Prescription Drug Cost-Sharing: Associations with Medication and Medical Utilization and Spending, and Health". *Journal of the American Medical Association (JAMA).* 2007; 29(1): 61-69.

Saigal C, Movassaghi M, **Joyce GF**, Pace JP, Litwin M. "Economic Evaluation of Treatment Strategies for Benign Prostatic Hyperplasia: Is Medical Therapy More Costly in the Long Run"? *Journal of Urology.* 2007; 177(4): 1463-7.

Joyce GF, Goldman DP, Karaca-Mandic P, Zheng Y. "Pharmacy Benefit Caps and the Chronically Ill". *Health Affairs.* 2007; 26(5): 1333-1344.

Meacham RB, **Joyce GF**, Wise M, Parker A, Niederberger C. "Male Infertility." *The Journal of Urology.* 2007; 177(6): 2058-2066.

Goldman DP, **Joyce GF**, Karaca-Mandic P, Sood N. "Adverse Selection in Retiree Prescription Drug Plans". *Forum for Health Economics & Policy:* 2006; Vol. 9: Iss. 1. (<http://www.bepress.com/fhep/9/1/4>).

Tash Anger J, Saigal CS, Madison R, **Joyce GF**, Litwin MS. Increasing Costs of Urinary Incontinence among Female Medicare Beneficiaries. *Journal of Urology.* 2006; Vol. 176(1): 247-251.

Goldman DP, **Joyce GF**, Lawless G, Willey V, Crown W. "Benefit Design and Specialty Drug Use." *Health Affairs.* 2006; 25(5): 1319-1331.

Fremont AM, **Joyce GF**, Anaya HD, et al. "An HIV Quality Improvement Collaborative within the VA: Do Advanced HIT and Shorter Learning Sessions Change the Collaborative Experience? *Joint Commission Journal on Quality and Patient Safety.* 2006; 32(6): 324-336.

Saigal C, **Joyce G**. Economic Costs of Benign Prostatic Hyperplasia in the Private Sector. *Journal of Urology*. 2006; 173:1309-1313. doi: 10.1097/01.ju.0000152318.79184.6f.

Goldman DP, **Joyce GF**, Karaca-Mandic P. “Optimal Drug Benefit Design: The Case of Cholesterol-Lowering Drug Therapy.” *American Journal of Managed Care*. 2006; 12(1): 21-28.

Joyce GF, Keeler EB, Shang B, Goldman DP. The Lifetime Burden of Chronic Disease Among the Elderly. *Health Affairs*. 2005; Web Exclusive (26 September): 18-29.

Meredith LS, Mendel P, Pearson M, Wu SY, **Joyce GF**, Straus JB, Ryan G and Unutzer J. “Success of Implementation and Maintenance of Quality Improvement for Depression.” *Psychiatric Services*. 2005; 57(1): 48-55.

Saigal CS, **Joyce GF**, Timilsina AR, and the Urologic Diseases in America Project. Direct and Indirect Costs of Nephrolithiasis in an Employed Population. *Kidney International*. 2005; 68(4): 1808-1814.

Baker DW, Asch SM, Keesey JW, Brown JA, Chan KS, **Joyce GF**, Keeler EB. Differences in Communication, Education, Self-Management Activities, and Health Outcomes for Patients with Heart Failure Cared for Under the Chronic Disease Model: The Improving Chronic Illness Care Evaluation. *Journal of Cardiac Failure*. 2005; 11(6): 405-413.

Goldman DP, Cutler D, Shang B, **Joyce GF**. The Value of Elderly Disease Prevention. *Forum for Health Economics & Policy*. 2005 (No. 1004).

Joyce GF, Chan K, Orlando M, Burnam MA. Mental Health Status and Use of General Medical Services for Persons with HIV. *Medical Care*. 2005; 43(8): 834-839.

Goldman DP, Shang B, Bhattacharya J, Garber AM, Hurd M, **Joyce GF**, Lakdawalla D, Panis S, Shekelle P. Health and Spending of the Future Elderly: Consequences of Health Trends and Medical Technology. *Health Affairs*. 2005; Web Exclusive (26 September): 5-17.

Saigal CS, **Joyce GF**. Economic Costs of Benign Prostatic Hyperplasia in the Private Sector. *Journal of Urology*. 2005; 173(4): 1309-1313.

Goldman DP, **Joyce GF**. Moving Towards Better Formulary Management. *American Journal of Managed Care*. 2005; 11(1): 13-14.

Joyce GF, Goldman DP, Leibowitz AA, Alpert A, Bao Y. Socioeconomic Circumstances of Older Adults with HIV. *Journal of Health Care for the Poor and Underserved*. 2005; 16:19-28.

Litwin MS, Saigal CS, Yano EM, et al. Urologic Diseases in America: Analytic Methods and Principal Findings. *Journal of Urology*. 2005; 173: 933-37.

Goldman DP, **Joyce GF**, Escarce JJ, et al. Pharmacy Benefits and Use of Drugs by the Chronically Ill. *Journal of the American Medical Association (JAMA)*. 2004; 291: 2344-2350.

Malkin JD, Goldman DP, **Joyce GF**. The Changing Face of Pharmacy Benefit Design. *Health Affairs*. 2004; 23(1): 194-199.

Chan K, Orlando M, **Joyce GF**, et al. Combination Antiretroviral Therapy and Improvements in Mental Health: Results from a Nationally Representative Sample of Persons Under Care for HIV in the U.S. *Journal of Acquired Immune Deficiency Syndrome (JAIDS)*. 2003; 33(1): 104-11.

Goldman DP, Leibowitz AA, **Joyce GF**, et al. Insurance Status of HIV-Infected Adults in the Post-HARRT Era. *Applied Health Economics and Health Policy*. 2003; 2(1): 85-91.

Lakdawalla D, Goldman DP, Bhattacharya J, Hurd MD, **Joyce GF**, Panis CW. Forecasting the Nursing Home Population. *Medical Care*. 2003; 41: 8-20.

Bhattacharya J, Cutler D, Goldman D, Hurd M, **Joyce G**, Lakdawalla D, Panis C, Shang B. Disability Forecasts and Future Medicare Costs. In *Frontiers in Health Policy Research 6*, edited by David Cutler and Alan Garber, NBER, Boston, MA: MIT Press, 2003.

Joyce GF, Escarce JJ, Solomon MD, Goldman DP. Employer Drug Benefit Plans and Spending on Prescription Drugs. *Journal of the American Medical Association (JAMA)*. 2002; 288:1733-1739.

Goldman DP, **Joyce GF**, Malkin J. The Costs of a Medicare Prescription Drug Benefit. *Topics in Economic Analysis & Policy*, 2002; 2(1): Article 3.

Bozzette SA, **Joyce GF**, McCaffrey DF, Leibowitz AA, et al. Changing Expenditures for HIV Care Among American Adults in the Era of Highly Active Therapy: Results from the HIV Cost and Services Utilization Study. *The New England Journal of Medicine*. 2001; 344: 817-823.

Escarce JJ, Kapur K, **Joyce GF**, Van Vorst KA. "Medical Care Expenditures under Gatekeeper and Point of Service Arrangements." *Health Services Research*. 2001; 36:1037-1057.

Goldman DP, Bhattacharya J, McCaffrey DF, Duan N, Leibowitz AA, **Joyce GF**, Morton SC. "The Effect of Insurance on Mortality in an HIV+ Population in Care". *The Journal of the American Statistical Association*. 2001; 96:1-12.

Zingmond DS, Wenger NS, Crystal S, **Joyce GF**, et al. "Circumstances at HIV Diagnosis and Progression of Disease in Older HIV-Infected Americans: Results from a Nationally Representative Sample of HIV-Infected Adults Receiving Care." *The American Journal of Public Health*. 2001; 91:1117-1120.

Goldman DP, Bhattacharya J, Leibowitz AA, **Joyce GF**, Shapiro MF, Bozzette SA. "The Impact of State Policy on the Costs of HIV Infection." *Medical Care Research and Review*. 2001; 58:31-53.

Joyce GF, Kapur K, Van Vorst KA, and Escarce JJ. "Visits to Primary Care Physicians and to Specialists under Gatekeeper and Point of Service Arrangements." *The American Journal of Managed Care*. 2000; 6: 1189-1196.

Kapur K, **Joyce GF**, Van Vorst KA, Escarce JJ. "Expenditures for Physician Services under Alternative Models of Managed Care." *Medical Care Research and Review*. 2000; 57: 161-181.

Joyce GF, Goldman DP, Leibowitz AA, Duan N, Carlisle D, Shapiro MF, Bozzette SA. "Variation in Inpatient Resource Use in the Treatment of HIV - Do the Privately Insured Receive More Care?" *Medical Care*. 1999; 37: 220-227.

B. Papers Submitted for Publication and Current Research

Joyce G, Kaestner R, Zhou B. A More Balanced Debate on Prescription Drug Costs and Spending. Under review at *JAMA Health Forum*.

Joyce, G., Zhou B, Kaestner R. Is Value-Based Insurance Design Relevant in Medicare Part D? Under review at the *American Journal of Health Economics*.

Trish E, Kaiser KM, Celestin J, **Joyce G**. The Growth and Impact of Enhanced Plans in Medicare Part D.

Joyce G, Zissimopoulos J, Zheng Y, Barofsky J, Goldman DP. The Impact of Medicare Part D on Part A and B Spending.

Lu Y, Ning N, Ding Y, Gascue L, **Joyce G**. The Impact of Black Box Warnings on Pharmaceutical Demand.

Joyce G, Lu Y, Ning N, Ding Y, Gascue L. Consequences of an FDA Safety Alert on the Use of Antidiabetic Medications.

Vogt W, **Joyce G**, Goldman DP. Effects of Medicare Part D on Pharmacy Use and Out-of-Pocket Spending.

Vogt W, **Joyce G**, Menchine M, Jena AB, Goldman DP. Effect of Medicaid Prior Authorization on Psychotropic Drug Utilization, Emergency Department Use and Hospitalizations among Patients with Schizophrenia.

C. Technical Reports & Working Papers

Mulligan K, Van Nuys K, Peneva D, Ryan M, **Joyce G**. The Value of Treatment for COVID-19. USC Schaeffer Center White Paper. July 2020.

Trish E, Kaiser K, **Joyce G**. How Would Sharing Rebates at the Point-of-Sale Affect Beneficiary Cost-Sharing in Medicare Part D? USC Schaeffer Center White Paper. March 2020.

Van Nuys K, **Joyce G**, Ribero R, Goldman D. Overpaying for Prescription Drugs: The Copay Clawback Phenomenon. USC Schaeffer Center White Paper. March 2018

Van Nuys K, **Joyce G**, Ribero R, Goldman D. A Perspective on Prescription Drug Copayment Coupons. USC Schaeffer Center White Paper. February 2018.

Joyce G, Chen S, Ribero R and Gascue L. Integrating Clinical Pharmacy Services in Safety Net Clinics. Final Report to the Center for Medicare and Medicaid Innovation. September 2016.

Joyce GF, Sabik L, Buntin MB. Redesigning Insurance Benefits to Promote Healthy Behaviors. 2008.

Keeler EB, **Joyce GF**. Costs and Effects of Participation in Collaboratives to Improve Chronic Illness Care. 2008.

Joyce GF, Sun E, Sood N, Goldman DP. "Drug Pricing and Formulary Coverage". July 2008.

Joyce GF, Goldman DP, Sun E, Sood N, Totten M, Huang M, and Spanos E. "A Comparison of Pharmacy Benefit Programs: Insights for Medicare Part D". September 2007.

Dai C, Karaca-Mandic P, Goldman DP, **Joyce GF**. The Effects of Cost-Sharing on Adherence to Antidepressants and Depression-Related Medical Expenditures. 2007.

Joyce GF, Schuster C, Trivedi M. "The Right Prescription for California? An Analysis of Propositions 78 and 79". Final Report for the California HealthCare Foundation, October 2005.

Joyce GF, Morton SC, Maglione M, Rastegar A, Newberry S, Cruz C, and Niaura R. "Evaluation of the Medicare Stop Smoking Program". Final Report, July 2005.

Joyce GF, Malkin JD and Pace J. "Pharmacy Use and Costs in the TRICARE Senior Pharmacy Program: Insights for Benefit Design from the Private Sector". MG-154-OSD, 2005.
Morton, SC, **Joyce GF**, Mongoven J, Maglione M, Rubenstein L, and Niaura R. "The Medicare Stop Smoking Program: Study Design, Methods and Baseline Characteristics".

Malkin JD, **Joyce GF**, Pace J, Croghan T. "Determinants of Dispensing Location in the Senior TRICARE Pharmacy Program". MG-237-OSD, 2005.

Goldman DP, Shekelle PG, Bhattacharya J, Hurd M, **Joyce GF**, Lakdawalla DN, Matsui DH, Panis CW, and Shang B. "Health Status and Medical Treatment of the Future Elderly". Technical Report. August 2004.

Joyce GF, Schuster C, Trivedi M. "State and Private Initiatives to Reduce Prescription Drug Prices for Lower-Income Americans". 2004

Matsuoka K, **Joyce GF**, Malkin JD, Pace J, and Croghan T. "Potentially Inappropriate Use of Pharmaceuticals by Elderly TRICARE Beneficiaries". DRR -3359-OSD, June 2004.

Joyce GF, Malkin JD. "The Impact of a Three-tier Drug Benefit". 2004

Joyce GF, Malkin JD, and Goldman DP. "The Cost of Reference-Priced Generic Drug Coverage". 2003.

Keeler EM, Guralnik JM, Leveille S, Tian H, **Joyce GF**, et al. "The Impact of Functional Status on Life Expectancy and Health Care Costs for Older Persons". 2003.

Joyce GF, and Schoenbaum M. "Patterns of Pharmaceutical Use Among Working Age and Medicare Eligible Adults with Private Insurance". June 2002.

Goldman D, Bhattacharya J, Leibowitz A, **Joyce G**, Shapiro M, and Bozzette S. "An Integrated Model of HIV Regulatory Policy". November 2000.

Shekelle P, Stone E, **Joyce G**, Wu S, et al. "Interventions to Promote Smoking Cessation in the Medicare Population", Evidence Report and Evidence-Based Recommendations. September 2000.

Goldman D, Jacobson J, Bhattacharya J, D'Amato R, **Joyce G**. Panis C, Shekelle P, Callahan C, and Hurd M. "Health Status and Medical Treatment of the Future Elderly", Findings from the Social Science Literature Review and Expert Panel. June 2000.

Joyce, G. "A New Index of Industrial Material Prices", *First Boston Working Paper Series*. Columbia University School of Business. August 1985.

D. Book Chapters

Goldman DP and **Joyce GF**. Consumer Demand and Health Effects of Cost Sharing. “The Oxford Handbook of the Economics of the Biopharmaceutical Industry,” edited by Patricia M. Danzon and Sean Nicholson. Oxford University Press, 2012.

McNaughton-Collins M, **Joyce GF**, Wise M, and Pontari MA. “Prostatitis”. Urologic Diseases in America. National Institute of Diabetes and Digestive and Kidney Diseases, US Department of Health and Human Services. 2007, Chapter 1, 9-42.

Clemens JQ, **Joyce GF**, Wise M, and Payne CK. “Interstitial Cystitis/Painful Bladder Syndrome”. Urologic Diseases in America. National Institute of Diabetes and Digestive and Kidney Diseases, US Department of Health and Human Services. 2007, Chapter 4, 123-156.

Konety BR, **Joyce GF**, and Wise M. “Bladder Cancer”. Urologic Diseases in America. National Institute of Diabetes and Digestive and Kidney Diseases, US Department of Health and Human Services. 2007, Chapter 7, 223-280.

Pohl HG, **Joyce GF**, Wise M, and Cilento BG. “Pediatric Urologic Disorders”. Urologic Diseases in America. National Institute of Diabetes and Digestive and Kidney Diseases, US Department of Health and Human Services. 2007, Chapter 11, 379-420.

Niederberger C, **Joyce GF**, Wise M, and Meacham. “Male Infertility”. Urologic Diseases in America. National Institute of Diabetes and Digestive and Kidney Diseases, US Department of Health and Human Services. 2007, Chapter 14, 459-482.

Wessels H, **Joyce GF**, Wise M, and Wilt TJ. “Erectile Dysfunction/Peyronie’s Disease”. Urologic Diseases in America. National Institute of Diabetes and Digestive and Kidney Diseases, US Department of Health and Human Services. 2007, Chapter 15, 483-530.

Santucci RA, **Joyce GF**, and Wise M. “Male Urethral Stricture Disease”. Urologic Diseases in America. National Institute of Diabetes and Digestive and Kidney Diseases, US Department of Health and Human Services. 2007, Chapter 16, 531-552.

Sokoloff MH, **Joyce GF**, and Wise M. “Testicular Cancer”. Urologic Diseases in America. National Institute of Diabetes and Digestive and Kidney Diseases, US Department of Health and Human Services. 2007, Chapter 17, 553-586.

Saigal CS, **Joyce GF**, Geschwind SA, and Litwin MS. “Methods”. Urologic Diseases in America. National Institute of Diabetes and Digestive and Kidney Diseases, US Department of Health and Human Services. 2007, Chapter 21, 697-738.

E. Letters

“Blame capitalism? Why hundreds of decades-old yet vital drugs are nearly impossible to find”. The Conversation, July 19, 2023. <https://theconversation.com/blame-capitalism-why-hundreds-of-decades-old-yet-vital-drugs-are-nearly-impossible-to-find-206848>

I wrongly expected COVID to fade last summer — here’s what to expect this time. MarketWatch, May 24, 2022. <https://www.marketwatch.com/story/i-wrongly-expected-covid-to-fade-last-summer-heres-what-to-expect-this-time-11653414220>

Covid-19 is on the run. MarketWatch, February 18, 2021. <https://www.marketwatch.com/story/covid-19-is-on-the-run-expect-the-pandemic-to-be-under-control-by-memorial-day-11613659943>

5 COVID-19 myths politicians have repeated that just aren’t true. *The Conversation*, July 8, 2020. <https://theconversation.com/5-covid-19-myths-politicians-have-repeated-that-just-arent-true-141972>

Are we overreacting to the coronavirus? Let’s do the math. MarketWatch, April 25, 2020. <https://www.marketwatch.com/story/are-we-overreacting-to-the-coronavirus-lets-do-the-math-2020-04-19>.

The success of Medicare Advantage makes it a better policy choice than ‘Medicare for All’. MarketWatch, November 19, 2019. <https://www.marketwatch.com/story/the-success-of-medicare-advantage-makes-it-a-better-policy-choice-than-medicare-for-all-2019-11-19>

An economist’s change of heart: It’s time to regulate the prescription-drug middlemen. MarketWatch, August 13, 2018. <https://www.marketwatch.com/story/an-economists-change-of-heart-its-time-to-regulate-the-prescription-drug-middlemen-2018-08-13>

Medicare’s ‘catastrophic insurance’ can be a catastrophe for middle-income seniors. STAT, July 23, 2018. <https://www.statnews.com/2018/07/23/medicare-catastrophic-insurance-a-catastrophe-for-some/> (with E. Trish).

Prescription Drug Coupons: A One-Size-Fits-All Policy Approach Doesn’t Fit the Evidence. Health Affairs Blog, February 16, 2018. <https://www.healthaffairs.org/doi/10.1377/hblog20180215.988517/full/> (With K. Van Nuys and R. Ribero).

House Plan to Replace Obamacare ‘Has Republican DNA,’ Especially Regarding Mandate. *The Conversation*, March 8, 2017. <https://theconversation.com/house-plan-to-replace-obamacare-has-republican-dna-especially-regarding-mandate-74246>.

No More Mylan Monopolies. U.S. News & World Report, August 30, 2016. <http://www.usnews.com/opinion/articles/2016-08-30/treat-epipen-and-generic-drugs-like-a-public-utility?int=a14709> (with N. Sood).

Clinton and Trump Are Both Wrong About Medicare and Negotiating Drug Prices. STAT. August 12, 2016. <https://www.statnews.com/2016/08/12/hillary-clinton-donald-trump-medicare/> (with N.Sood).

Why Are Some Generic Drugs Getting So Expensive? *The Conversation*, January 21, 2015. <https://theconversation.com/why-are-some-generic-drugs-getting-so-expensive-35603>.

“A Simple Rx for Medicare Part D”. *United Press International*. January 13, 2006.

“Financial Consequences of Drug Benefit Plans”. *JAMA*. 2003;289:423-424 (with D. Goldman).

“Take Two Aspirin and Call Congress”. *Los Angeles Times*. December 12, 2002 (with D. Goldman).

“Expenditures for the Care of Patients with HIV”. *The New England Journal of Medicine*. 2001; 344:1948-1949 (with S. Bozzette and D. McCaffrey).

“A Third — and Better — Way for Prescription Drug Coverage”. *Los Angeles Times*. November 5, 2000 (with D. Goldman).

HONORS, FELLOWSHIPS AND AWARDS

Medal Award, RAND, 2009.

President's Award, RAND, 2007-2008.

Career Development Award, UCLA Claude D. Pepper Center (OAIC), 2003-2006.

Medal Award, RAND, 2006

Exceptional Reviewer, Medical Care 2003-2004.

Medal Award, RAND, 2004

PROFESSIONAL ACTIVITIES

Member: NBER, AcademyHealth

Referee: Journal of Health Economics, Health Services Research, Journal of the American Medical Association, New England Journal of Medicine, Canadian Medical Journal, Medical Care, Health Affairs, Inquiry, Medical Care Research and Review, American Journal of Managed Care, Archives of General Psychiatry, Journal of the Operational Research Society, Journal of Acquired Immune Deficiency Syndrome, Journal of Disease Management, American Journal of Pharmacy Benefits.

Consultant: Substance Abuse and Mental Health Services Administration (SAMHSA)

INVITED PRESENTATIONS (selected)

Association of Out-of-Pocket Spending with Insulin Adherence in Medicare Part D. Association of Public Policy Analysis and Management (APPAM) Annual Conference. November 2020.

Variation in Generic Drug Use in Medicare Part D. Association of Public Policy Analysis and Management (APPAM) Annual Conference. Denver, CO. November 2019.

Universal Health Care: Exploring the Path Ahead. Panelist. KPCC In-Person Forum. Los Angeles, CA. June 2019.

Economics of the Health Care Industry. American Orthopedic Association (AOA), Chicago, IL. February 2019.

Delegating Decision-Making to the Machine – Experimental Evidence from Health Insurance (Discussant). American Economic Association (AEA) Annual Meeting, Chicago, IL. January 2019.

Modernizing Medicare Part D: Panel Discussion. Brookings Institute. Washington, DC. October 2018.

Generic Drug Price Hikes and Out-of-Pocket Costs of Medicare Beneficiaries. Value of Life Sciences Initiative Advisory Board. Washington, DC. October 2018.

Are Drug Prices Too High? If So, Why? Society of Utah Medical Oncologists (SUMO). Park City, UT, September 2018.

Drug Prices and Copay Coupons. Coalition of State Rheumatology Organizations (CSRO). Chicago, IL, September 2018.

Are Drug Prices Too High? If So, Why? Washington State Medical Oncology Society. Seattle, WA, July 2018.

Sex and Race Differences in the Association Between Statin Use and the Incidence of Alzheimer's Disease. Society for Brain Mapping and Therapeutics (SBMT) Alzheimer's Disease Conference 2018. Los Angeles, CA, April 2018.

Strategies for Improving the Affordability of High-Quality Care and Coverage. USC Schaeffer Center and National Coalition on Health Care. Los Angeles, CA, March 2018.

Patient Cost Sharing for Prescription Drugs: Policy Issues. A USC-Brookings Schaeffer Initiative for Health Policy Event. The Brookings Institution, Washington, DC. February, 2018.

Much Ado About Generics. UCLA Seminar on Pharmaceutical Economics and Policy. Los Angeles, CA. October, 2017.

California Health Care Summit: Strategies for Improving the Affordability of Care and Coverage National Coalition on Health Care. Sacramento, CA. September, 2017.

Managing Drug Benefits in the Context of Health Reform. Avanir Pharmaceuticals. Aliso Viejo, CA. May, 2017.

The Value of Innovation and New Payment Policies College of Wound Healing Annual Conference. Keynote Speaker, Chicago, IL. December 2016.

Out-of-Pocket Burden among Specialty Drug Users in Medicare Part D. USC Schaeffer Advisory Board Meeting. Brookings Institute. Washington, DC. March 2016.

Research Development and Drugs Pricing in a Global Economic Environment. R&D, Value of Innovation, and US-EU Pricing Policies University of California at San Francisco. San Francisco, CA. June, 2015.

Medications and the Health Care Cost Conundrum in Covered California California Pharmacists Association. Corporate Advisory Council. Dana Point, CA. March, 2015.

Making Health Care Affordable: What's Driving Costs. Public Testimony to the California Senate Health Committee. Sacramento, CA. Feb, 2015.

Re-Thinking Value in Health Care. QSAD Annual Conference, USC School of Pharmacy. Rancho Mirage, CA. January 2015.

The Impact of the Affordable Care Act on the Treatment of Diabetes Diabetes Mine Innovation Summit. Stanford University. November, 2014.

Integrating Clinical Pharmacists into Safety-Net Clinics. Centers for Medicare and Medicaid Services, Innovation Summit. Baltimore, MD. October, 2014.

Patient-Centered Diabetes Care: Putting Theory in to Practice. American Journal of Managed Care, Princeton, NJ. April 2014.

Measuring Value in Health Care. Optimizing Medication Safety and Healthcare Quality. Los Angeles, CA. February 2014.

The Impact of the Affordable Care Act on Surgeons. Pacific Coast Surgical Association, Annual Meeting. Dana Point, CA. February 2014.

Changing Perspectives 2013, Panelist. California Healthcare Institute, San Francisco, CA, December 2013.

Integrating Clinical Pharmacy Services in Primary Care. Board of Councilors Meeting, USC School of Pharmacy. December, 2013.

Healthcare Reform. USC Medical Management Program. Marshall School of Business, November, 2013.

The Economics of Health Reform. QSAD Annual Conference, USC School of Pharmacy. Santa Barbara, CA, January 2013.

Integrating Clinical Pharmacy Services in Primary Care. Board of Councilors Meeting. USC School of Pharmacy. Los Angeles, CA. November, 2012.

USC Medical Management Program. Healthcare Reform. Marshall School of Business, November, 2012.

Healthcare Partners Annual Meeting, Keynote Speaker. The Affordable Care Act and Physician Practice. Dana Point, CA. October, 2012.

Legislative Day. The Changing Role of Pharmacists. USC School of Pharmacy. October, 2012.

American Society of Health Economists (ASHE), Annual Meeting. Medicare Part D and the Doughnut Hole. Minneapolis, MN. June, 2012.

National Bureau of Economic Research, Health (NBER) Economics Spring Meeting. Digesting the Doughnut Hole. Cambridge, MA, April 2012.

The Science of Medicare Reform. The Implications of the Medicare Part D Coverage Gap. University of Southern California, Los Angeles, CA. January, 2012.

American Economic Association (AEA), Annual Meeting. Digesting the Doughnut Hole. Chicago, IL January, 2012.